Jun 11, 2025 Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma Learn More
Jun 5, 2025 Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules Learn More
Jun 4, 2025 Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM) Learn More
May 13, 2025 Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update Learn More